instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
The story makes it clear that cost of the test is currently speculative (“could cost about $500”) and goes even further to caution that: “Johns Hopkins holds the patent and has not licensed it as yet to a company that would ultimately set the price.” The story makes the two key results of the test quite clear. First, that the 1,005 people tested already had been diagnosed with one of eight common cancers, and the blood test was able to detect cancer in about 70 percent of them. Second, the test was also given to 812 people without cancer and only a false reading for cancer less than 1 percent of the time. Including the additional finding that the test was only able to detect cancer in about 40 percent of the patients with early cancer (ie. stage I) was a thoughtful way of introducing the relevant issue of falsely negative tests. The story does an excellent job of finding an independent source who explains that one of the potential risks of cancer screening tests is either identifying cancers that are not there, or are benign, and can lead to “pointless and potentially dangerous treatments.” The opposite harm is also mentioned; that is, a screening test that erroneously gives a negative result, leading providers to falsely reassure a patient that cancer is not there. Cautious language is used at many points in the story and it does three things quite well. First, it lists the most important limitation of the study: The screening test studied was unable to identify the type of cancer. Second, the implications of both falsely positive and falsely negative tests were explained succinctly and placed in a clinical context that would matter to those undergoing screening. Finally, we were very encouraged by the inclusion of this sentence: “… the researchers will still have to demonstrate that the test improves and extends the lives of cancer patients.” There is no disease mongering in this story. The two independent sources cited provide important context for understanding the strengths, limitations, and clinical context of the screening test. This was a tough call, but ultimately we felt the story would have been stronger had it mentioned the performance of current screening methods for some of the cancer types, such as Cologuard for colon cancer. That said, we were glad the story included some of the pitfalls of screening for prostate and breast cancer, as well as the long struggle to develop more blood tests for cancer. It’s mentioned the authors of the study are “hoping their idea would eventually lead to a $500 test … but they have a long way to go.” Future studies of the screening test are also discussed, so it seems clear this test is not currently available. It’s made clear that “there have been many attempts over the decades to develop blood tests to screen for cancers … but these methods don’t give reliable results.” It’s also pointed out that what makes this screening test unique is that it combines two previously used methods (screening for proteins and for DNA) into one test. This story does not appear to rely upon a news release.
answer:
Scientists Edge Closer To A Blood Test To Detect Cancers


question:
Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.
answer:
Eli Lilly drops inhaled insulin program.


question:
If you die an untimely death, can you have your ashes sent to the person of your choice? What if you would like to send it to your least favorite representative in order to protest legislation they have written or voted for? In theory, it is already possible to have your cremated remains sent to Congress, but the idea has gained traction as a political protest since the passage of the American Health Care Act in the House on 4 May 2017. Shortly after it passed, 20-year-old Zoey Jordan Salsbury revealed that she had created “Mail Me to the GOP”, a web site that offers to help users get their paperwork in order to send their ashes to a “GOP member of Congress” when they die. The site also links to an online fundraiser seeking to unseat the members of Congress who voted for the bill. Salsbury, a junior at American University who won the President’s Volunteer Service Award alongside a friend last year for her online work, lives with depression and anxiety, and was also diagnosed with fibromyalgia in November 2016. She told us: I have several pre-existing conditions that are out of my control. They are things I was born with. And when you have chronic illnesses you befriend others with chronic illness. So I have friends who I see struggle with expensive care, even with insurance. I know they’ll die if the bill is passed by the Senate. I know I’ll die if I can’t afford my psych and pain meds. And I wanted the GOP to see that. The website asks users, “Why will you die because of the Republican health care bill?” and asks them to submit responses. As of 8 May 2017, Salsbury said, just over 1,100 people had signed up to take part in the process, adding: “I’m sure there are a few trolls in there, but from what I’ve scrolled through and seen most are genuine.” However, she said, she will not personally send the cremated remains; instead she planned to help people work with an estate planner in order to make their own arrangements should they choose to follow through with the posthumous protest statement. But as her site has received more notice, Salsbury said, her server has crashed multiple times. She told us: I’m really glad that it’s gotten so much attention. I really hope it makes an impact on GOP members of the Senate. It’s been picked up by some right-wing blogs which has made my Twitter mentions and Facebook messages kind of a nightmare, but it’s worth all the hate if even one member of the Senate votes against this bill because of it. The United States Postal Service does allow the shipment of cremated remains, so long as they are mailed in a package containing padding as well as inner and outer containers. Salsbury said she would do more research”on the legalities of sending ashes to lawmaker after the Senate takes up the matter. “Right now I want to concentrate on making sure this bill dies in the Senate, instead of us dying,” Salsbury told us. Sen. Susan Collins (R-Maine) has said that her colleagues would start over again “from scratch” instead of considering the House version of the bill. We contacted USPS seeking comment regarding any possible special stipulations regarding mail to the Capitol, but have not yet received a response.
answer:

If you die, you can send your ashes to legislators as one final act of protest.